SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug could make curative transplant safer for bone marrow cancer patients
Disease control OngoingThis study is testing whether giving the drug ruxolitinib before, during, and after a stem cell transplant can reduce dangerous complications and improve survival for people with myelofibrosis, a serious bone marrow cancer. A stem cell transplant is currently the only treatment w…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New combo therapy tested for tough blood cancer cases
Disease control OngoingThis study is testing whether combining two drugs, fedratinib and nivolumab, can help control myelofibrosis, a serious bone marrow cancer, in patients whose disease did not respond well to standard JAK-inhibitor therapy. It will involve about 30 adults with primary or secondary m…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: SECONDARY MYELOFIBROSIS
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New Two-Part strategy aims to tame bone marrow cancer before transplant
Disease control OngoingThis study is testing a two-step treatment for myelofibrosis, a serious bone marrow cancer. First, patients take a JAK inhibitor drug (ruxolitinib) for at least 8 weeks to try to reduce symptoms and improve their health. Then, they receive a stem cell transplant from a donor, whi…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 09, 2026 14:22 UTC